Patient Perceptions of Exertion and Dyspnea With Interleukin-1 Blockade in Patients With Recently Decompensated Systolic Heart Failure.

[1]  C. Trankle,et al.  Interleukin-1 blockade with Anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials. , 2021, European heart journal. Cardiovascular pharmacotherapy.

[2]  D. Mancini,et al.  Predictive Value of Cardiopulmonary Exercise Testing Parameters in Ambulatory Advanced Heart Failure. , 2021, JACC. Heart failure.

[3]  J. Canada,et al.  Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II–III Systolic Heart Failure , 2020, Journal of cardiovascular pharmacology.

[4]  W. Shimizu,et al.  Patient‐reported outcomes in heart failure with preserved vs. reduced ejection fraction: focus on physical independence , 2020, ESC heart failure.

[5]  R. Arena,et al.  Cardiopulmonary exercise testing – refining the clinical perspective by combining assessments , 2020, Expert review of cardiovascular therapy.

[6]  B. V. Van Tassell,et al.  Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease , 2020, Circulation research.

[7]  T. Murohara,et al.  Reduced exercise capacity and clinical outcomes following acute myocardial infarction , 2020, Heart and Vessels.

[8]  Dave L Dixon,et al.  Interleukin‐1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST‐Segment–Elevation Myocardial Infarction , 2020, Journal of the American Heart Association.

[9]  R. Arena,et al.  Determinants of Cardiorespiratory Fitness in Patients with Heart Failure Across a Wide Range of Ejection Fractions. , 2019, The American journal of cardiology.

[10]  R. Arena,et al.  Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.

[11]  R. Arena,et al.  C-Reactive Protein and N-Terminal Pro-brain Natriuretic Peptide Levels Correlate With Impaired Cardiorespiratory Fitness in Patients With Heart Failure Across a Wide Range of Ejection Fraction , 2018, Front. Cardiovasc. Med..

[12]  R. Arena,et al.  Usefulness of Canakinumab to Improve Exercise Capacity in Patients With Long-Term Systolic Heart Failure and Elevated C-Reactive Protein. , 2018, The American journal of cardiology.

[13]  Dave L Dixon,et al.  Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial) , 2017, Circulation. Heart failure.

[14]  A. Domínguez-Rodríguez,et al.  Cardiopulmonary Exercise Testing Versus 6-Min Walk Test as Clinically Meaningful Endpoints in HF Trials. , 2017, Journal of the American College of Cardiology.

[15]  H. Knoop,et al.  Interleukin-1 as a mediator of fatigue in disease: a narrative review , 2017, Journal of Neuroinflammation.

[16]  J. Lasselin,et al.  Role of Inflammation in Human Fatigue: Relevance of Multidimensional Assessments and Potential Neuronal Mechanisms , 2017, Front. Immunol..

[17]  G. Barbati,et al.  Prognostic value of cardiopulmonary exercise testing in Idiopathic Dilated Cardiomyopathy. , 2016, International journal of cardiology.

[18]  Gemma Navarro,et al.  The Minnesota living with heart failure questionnaire: comparison of different factor structures , 2016, Health and Quality of Life Outcomes.

[19]  S. Hummel,et al.  Symptom burden in heart failure: assessment, impact on outcomes, and management , 2016, Heart Failure Reviews.

[20]  G. Biondi-Zoccai,et al.  Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). , 2014, The American journal of cardiology.

[21]  E. Ashley,et al.  Effects of respiratory exchange ratio on the prognostic value of peak oxygen consumption and ventilatory efficiency in patients with systolic heart failure. , 2013, JACC. Heart failure.

[22]  R. Arena,et al.  Enhanced Interleukin-1 Activity Contributes to Exercise Intolerance in Patients with Systolic Heart Failure , 2012, PloS one.

[23]  R. Arena,et al.  Cardiopulmonary exercise testing is a core assessment for patients with heart failure. , 2011, Congestive heart failure.

[24]  D. Bensimhon,et al.  Ventilatory efficiency and dyspnea on exertion improvements are related to reduced pulmonary pressure in heart failure patients receiving Sildenafil. , 2010, International journal of cardiology.

[25]  D. Bensimhon,et al.  Maximal dyspnea on exertion during cardiopulmonary exercise testing is related to poor prognosis and echocardiography with tissue Doppler imaging in heart failure. , 2009, Congestive heart failure.

[26]  E. Bocchi,et al.  The Borg scale as an important tool of self-monitoring and self-regulation of exercise prescription in heart failure patients during hydrotherapy. A randomized blinded controlled trial. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[27]  D. Bensimhon,et al.  Determining the Preferred Percent-Predicted Equation for Peak Oxygen Consumption in Patients With Heart Failure , 2009, Circulation. Heart failure.

[28]  K. Albouaini,et al.  Cardiopulmonary exercise testing and its application , 2007, Postgraduate Medical Journal.

[29]  J. Davis,et al.  Role of brain IL-1beta on fatigue after exercise-induced muscle damage. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.

[30]  M. Madigan,et al.  Predicting peak oxygen consumption during a conservative ramping protocol: implications for the heart failure population. , 2003, Journal of cardiopulmonary rehabilitation.

[31]  M. Peberdy,et al.  Using the Duke Activity Status Index in heart failure. , 2002, Journal of cardiopulmonary rehabilitation.